The wound/burn guidelines - 4: Guidelines for the management of skin ulcers associated with connective tissue disease/vasculitis

J Dermatol. 2016 Jul;43(7):729-57. doi: 10.1111/1346-8138.13275. Epub 2016 Mar 12.

Abstract

The Japanese Dermatological Association prepared guidelines focused on the treatment of skin ulcers associated with connective tissue disease/vasculitis practical in clinical settings of dermatological care. Skin ulcers associated with connective tissue diseases or vasculitis occur on the background of a wide variety of diseases including, typically, systemic sclerosis but also systemic lupus erythematosus (SLE), dermatomyositis, rheumatoid arthritis (RA), various vasculitides and antiphospholipid antibody syndrome (APS). Therefore, in preparing the present guidelines, we considered diagnostic/therapeutic approaches appropriate for each of these disorders to be necessary and developed algorithms and clinical questions for systemic sclerosis, SLE, dermatomyositis, RA, vasculitis and APS.

Keywords: antiphospholipid antibody syndrome; dermatomyositis; rheumatoid arthritis; systemic lupus erythematosus; vasculitis.

Publication types

  • Practice Guideline

MeSH terms

  • Antithrombins / therapeutic use
  • Calcinosis / complications*
  • Calcinosis / diagnosis
  • Calcinosis / therapy
  • Calcium Channel Blockers / therapeutic use
  • Connective Tissue Diseases / complications*
  • Dapsone / therapeutic use
  • Endothelin Receptor Antagonists / therapeutic use
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Leukapheresis
  • Phosphodiesterase 5 Inhibitors / therapeutic use
  • Platelet Aggregation Inhibitors / therapeutic use
  • Prostaglandins / therapeutic use
  • Skin Ulcer / drug therapy*
  • Skin Ulcer / etiology
  • Skin Ulcer / surgery
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Vasculitis / complications*

Substances

  • Antithrombins
  • Calcium Channel Blockers
  • Endothelin Receptor Antagonists
  • Glucocorticoids
  • Immunosuppressive Agents
  • Phosphodiesterase 5 Inhibitors
  • Platelet Aggregation Inhibitors
  • Prostaglandins
  • Tumor Necrosis Factor-alpha
  • Dapsone